Seminars in Oncology
Volume 36 , Pages S35-S45 , August 2009

Diagnostic Tools for Neoplastic Meningitis: Detecting Disease, Identifying Patient Risk, and Determining Benefit of Treatment

  • Marc C. Chamberlain

      Affiliations

    • Department of Neurology and Neurological Surgery, Division of Neuro-Oncology, University of Washington, Seattle, WA
    • Corresponding Author InformationAddress correspondence to Marc Chamberlain, MD, University of Washington, Department of Neurology and Neurological Surgery, Chief, Division of Neuro-Oncology, Seattle Cancer Care Alliance, 825 Eastlake Ave E, Mail Stop G4-940, Seattle, WA 98109-1023
    • ,
  • Michael Glantz

      Affiliations

    • Department of Neurosurgery, Penn State Hershey Medical Center, Hershey, PA
    • ,
  • Morris D. Groves

      Affiliations

    • The University of Texas, M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Wyndham H. Wilson

      Affiliations

    • Lymphoma Therapeutics Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

References 

  1. Posner JB. Leptomeningeal metastases. In: (ed 1). Neurologic complications of cancer. vol 45:New York: Oxford University Press; 1995;p. 143–171
  2. Chamberlain MC. Neoplastic meningitis. Neurologist. 2006;12:179–187
  3. Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979;29:1369–1375
  4. Enting RH. Leptomeningeal neoplasia: epidemiology, clinical presentation, CSF analysis and diagnostic imaging. Cancer Treat Res. 2005;125:17–30
  5. Chamberlain MC, Junck L. Defining patients at risk for neoplastic meningitis: what parameters can be used to determine who should be treated?. Expert Rev Neurother. 2004;4(Suppl):S3–S10
  6. Glantz MJ, Chamberlain MC, Walters BC. Diagnosis and outcome measures in trials for neoplastic meningitis: a review of the literature and clinical experience. Neurosurg Focus. 1998;4:8–16
  7. Chamberlain MC, Kormanik PA. Carcinomatous meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol. 1998;55:506–512
  8. Chamberlain MC, Kormanik P. Prognostic significance of co-existent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol. 1997;54:1364–1368
  9. Harstad L, Hess KR, Groves MD. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neurooncology. 2008;10:1010–1018
  10. Chamberlain MC, Kormanik P. Prognostic significance of 111 indium-DTPA CSF flow studies. Neurology. 1996;46:1674–1677
  11. Chamberlain MC, Tsao-Wei D. Neoplastic meningitis-related encephalopathy: prognostic significance. Neurology. 2005;63:2159–2161
  12. Chamberlain MC, Glantz MJ, Johnston S. Neoplastic meningitis: prognostic significance of Karnofsky performance status. Arch Neurol. 2009;66:74–78
  13. Glantz MJ, Cole BF, Glantz LK, Cobb J, Mills P, Lekos A, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82:733–739
  14. Chamberlain MC, Kormanik PA, Glantz MJ. A comparison between ventricular and lumbar CSF cytology in adult patients with leptomeningeal metastases. Neurooncology. 2001;3:42–45
  15. Chamberlain MC, Sandy A, Press GA. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology. 1990;40:435–438
  16. Zeiser R, Burger JA, Bley TA, Windfuhr-Blum M, Schulte-Monting J, Behringer DM. Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis—a single centre experience. Br J Haematol. 2004;124:762–768
  17. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate grade and immunoblastic lymphoma. Blood. 1998;91:1178–1184
  18. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol. 2002;13:1099–1107
  19. Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105:496–502
  20. French CA, Dorfman DM, Shaheen G, Cibas ES. Diagnosing lymphoproliferative disorders involving the cerebrospinal fluid: increased sensitivity using flow cytometric analysis. Diagn Cytopathol. 2000;23:369–374
  21. Bromberg JEC, Breems DA, Kraan J, Bikker G, van der Holt B, Sillevis Smitt P, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology. 2008;68:1674–1679
  22. Brem SS, Bierman PJ, Black P, Brem H, Chamberlain M, Chiocca EA, et al. NCCN clinical practice guidelines in oncology (Central nervous system cancers). V.1.2008 ed http://www.nccn.org/professionals/physician_gls/PDF/cns.pdfAccessed January 23, 2009
  23. Rhodes CH, Glantz MJ, Glantz L, Lekos A, Sorenson GD, Honsinger C, et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer. 1996;77:543–548
  24. Gleissner B, Siehl J, Korfel A, Reinhardt R, Thiel E. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology. 2002;58:390–396
  25. Chamberlain MC. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology. 1998;50:1173–1175
  26. Twijnstra A, Ongerboer de Visser BW, van Zanten AP, Hart AA, Nooyen WJ. Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors. J Neurooncol. 1989;7:57–63
  27. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18:149–157
  28. Yoshida S, Morii K. Intrathecal chemotherapy for patients with meningeal carcinomatosis. Surg Neurol. 2005;63:52–55
  29. Groves MD. The pathogenesis of neoplastic meningitis. Curr Oncol Rep. 2003;5:15–23
  30. Brandsma D, Voest EE, de Jager W, Bonfrer H, Algra A, Boogerd W, et al. CSF protein profiling using Multiplex Immuno-assay: a potential new diagnostic tool for leptomeningeal metastases. J Neurol. 2006;253:1177–1184
  31. van de Langerijt B, Gijtenbeek JM, de Reus HP, Sweep FC, Geurts-Moespot A, Hendriks JC, et al. CSF levels of growth factors and plasminogen activators in leptomeningeal metastases. Neurology. 2006;67:114–119
  32. Reijneveld JC, Brandsma D, Boogerd W, Bonfrer JG, Kalmijn S, Voest EE, et al. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology. 2005;65:1120–1122
  33. Friedberg MH, Glantz MJ, Klempner MS, Cole BF, Perides G. Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer. 1998;82:923–930
  34. Herrlinger U, Wiendl H, Renninger M, Förschler H, Dichgans J, Weller M. Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer. 2004;91:219–224
  35. Stockhammer G, Poewe W, Burgstaller S, Deisenhammer F, Muigg A, Kiechl S, et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology. 2000;54:1670–1676
  36. Nagai A, Terashima M, Harada T, Shimode K, Takeuchi H, Murakawa Y, et al. Cathepsin B and H activities and cystatin C concentrations in cerebrospinal fluid from patients with leptomeningeal metastasis. Clin Chim Acta. 2003;329:53–60
  37. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008;26:96–105
  38. Chamberlain MC, Corey-Bloom J. Leptomeningeal metastasis: Indium-DTPA CSF flow studies. Neurology. 1991;41:1765–1769
  39. Groves MD. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology. 2006;66:1609–1610
  40. Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol. 2002;20:3445–3453
  41. Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21:2529–2536
  42. Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004;22:157–165
  43. Chamberlain MC, Johnston SK. Neoplastic meningitis: survival as a function of cerebrospinal fluid cytology. Cancer. 2009;115:1941–1946
  44. Chamberlain MC. Neoplastic meningitis. Oncologist. 2008;13:967–977
  45. Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neurooncology. 2008;10:208–215
  46. Chamberlain MC, Kormanik P. Leptomeningeal metastases due to melanoma: combined modality therapy. Int J Oncol. 1996;9:505–510
  47. Chamberlain MC, Kormanik PA. Non-AIDS related lymphomatous meningitis: combined modality therapy. Neurology. 1997;49:1728–1731
  48. Chamberlain MC, Kormanik PA. Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol. 1997;35:55–64
  49. Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 2006;24:5658–5663
  50. Wolstenholme V, Hawkins M, Ashley S, Tait D, Ross G. HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. Breast. 2008;17:661–665
  51. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first line treatment (The M77001 Study Group). J Clin Oncol. 2005;23:4265–4274
  52. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst. 2008;100:1092–1103
  53. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743
  54. Melisko ME, Glantz M, Rugo HS. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol. 2009;6:25–33
  55. Chamberlain MC. Risk of neoplastic meningitis following surgical resection of cerebellar metastases. J Neurooncol. 2008;89:105–107
  56. Suki D, Abouassi H, Patel AJ, Sawaya R, Weinberg JS, Groves MD. Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. J Neurosurg. 2008;108:248–257

 STATEMENT OF CONFLICT OF INTEREST: All four authors have received honorarium from Enzon Pharmaceuticals, as well as serving on the Enzon speaker's bureau. M.G. and M.D.G. have received research support from Enzon Pharmaceuticals.

PII: S0093-7754(09)00095-5

doi: 10.1053/j.seminoncol.2009.05.005

Seminars in Oncology
Volume 36 , Pages S35-S45 , August 2009

Article Tools

* Image Usage & Resolution